Publicly available records indicate that a class action lawsuit has been filed on behalf of investors in Indivior PLC (OTC:INVVY) in connection to alleged securities law violations by INVVY. Fitapelli Kurta is interested in hearing from investors who have complaints regarding investments made in Indivior PLC between March 10, 2015 and April 9, 2019.
The class action complaint specifically alleges that during the period in question, INVVY provided false and/or misleading material information and/or failed to disclose adverse material information to the public, namely: that the company as well as its executive officers participated in a scheme designed to increase prescriptions of Suboxone Film; that in connection with this scheme, the company unlawfully gained billions in revenue as a result of the increase in Suboxone prescriptions obtained through deception of healthcare professionals and programs; that this conduct would lead to felony charges for the company; and that consequently the company’s statements to the public during the relevant period were false and misleading. The complaint alleges that when true facts emerged, investors suffered losses.
According to the company’s website, Indivior PLC is a medical company that describes itself as a “world leader in addiction treatment with over 20 years of experience and a patient-focused approach.” The company describes its goals as the advancement of scientific and social understanding of addiction, and the activation of global partnerships to make resources more accessible for patients. Its product pipeline includes “buprenorphine 1-month depot in Atrigel,” “Oral orexin-1 receptor antagonist,” “GABA-B Positive Allosteric Modulator,” “Arbaclofen Placarbil,” and “RBP-7000.” The company trades over-the-counter under the symbol INVVY.